Role of Gp91 in Hepatic Macrophage Programming and Alcoholic Liver Disease
Overview
Authors
Affiliations
Hepatic macrophages (Ms) are important in the development and progression of alcoholic liver disease (ALD). This study investigates the role of gp91 (nicotinamide adenine dinucleotide phosphate oxidase 2) in the severity of ALD and specifically in regulating hepatic M efferocytic capability and the subsequent reprogramming associated with resolution of inflammation. After 4 weeks of ethanol feeding, more severe ALD developed in gp91 mice than in wild-type (WT) C57Bl/6J mice, evidenced by increased liver injury and inflammation. This phenomenon was not sex dependent, and thus the majority of experiments were performed with female mice. While total hepatic M numbers did not differ between genotypes, hepatic infiltrating Ms (IMs) were slightly more numerous in gp91 mice, and both IMs and resident Kupffer cells displayed enhanced proinflammatory and reduced tissue-restorative programming compared with these cells from WT mice. The ratio of proinflammatory IMs with higher expression of Ly6C (Ly6C) to anti-inflammatory IMs with lower expression of Ly6C (Ly6C) was significantly higher in gp91 mice compared to WT mice. Greater numbers of apoptotic cells accumulated in the liver of gp91 mice compared to WT mice, and receptors for binding and engulfing apoptotic cells were expressed at much lower levels on both Kupffer cells and IMs of gp91 mice. Interactions with apoptotic cells (binding and engulfment) were significantly fewer for gp91 Ms than for WT Ms, resulting in diminished expression of tissue restorative mediators by hepatic Ms of gp91 mice. : gp91 plays a critical role in the differentiation of proinflammatory hepatic Ms to a tissue-restorative phenotype, likely through programming for efferocytosis, and thereby lessens the severity of ALD. These findings enhance our understanding of the tissue environmental cues that regulate M phenotypes. This knowledge could help in designing M-targeting strategies to prevent and treat ALD. ( 2017;1:765-779).
Alcohol, Inflammation, and Microbiota in Alcoholic Liver Disease.
Dukic M, Radonjic T, Jovanovic I, Zdravkovic M, Todorovic Z, Kraisnik N Int J Mol Sci. 2023; 24(4).
PMID: 36835145 PMC: 9966185. DOI: 10.3390/ijms24043735.
Resolvin D1 attenuated liver injury caused by chronic ethanol and acute LPS challenge in mice.
Hardesty J, Warner J, Song Y, Rouchka E, McClain C, Warner D FASEB J. 2022; 37(1):e22705.
PMID: 36520060 PMC: 9832974. DOI: 10.1096/fj.202200778R.
The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective.
De Muynck K, Vanderborght B, Van Vlierberghe H, Devisscher L Cells. 2021; 10(11).
PMID: 34831182 PMC: 8616442. DOI: 10.3390/cells10112959.
Immunopathobiology and therapeutic targets related to cytokines in liver diseases.
He Y, Hwang S, Ait Ahmed Y, Feng D, Li N, Ribeiro M Cell Mol Immunol. 2020; 18(1):18-37.
PMID: 33203939 PMC: 7853124. DOI: 10.1038/s41423-020-00580-w.
Wen Y, Lambrecht J, Ju C, Tacke F Cell Mol Immunol. 2020; 18(1):45-56.
PMID: 33041338 PMC: 7852525. DOI: 10.1038/s41423-020-00558-8.